| 8.01 -0.52 (-6.1%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.69 |
1-year : | 11.66 |
| Resists | First : | 9.15 |
Second : | 9.98 |
| Pivot price | 8.96 |
|||
| Supports | First : | 7.8 |
Second : | 6.48 |
| MAs | MA(5) : | 8.36 |
MA(20) : | 9.08 |
| MA(100) : | 9.24 |
MA(250) : | 9.03 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 20.6 |
D(3) : | 19.8 |
| RSI | RSI(14): 37.5 |
|||
| 52-week | High : | 19.14 | Low : | 3.92 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ATRA ] has closed above bottom band by 2.2%. Bollinger Bands are 4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.3 - 8.34 | 8.34 - 8.39 |
| Low: | 7.67 - 7.72 | 7.72 - 7.78 |
| Close: | 7.91 - 8 | 8 - 8.1 |
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA2431 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.
Sat, 31 Oct 2026
Atara Biotherapeutics, Inc. (ATRA) Seasonal returns chart - Yahoo Finance UK
Wed, 28 Oct 2026
ATRA Q3'26 Earnings: EPS estimate is (0.13) USD - TradingView
Fri, 23 Oct 2026
Atara Biotherapeutics, Inc. Estimates – NASDAQ:ATRA - TradingView
Sun, 06 Sep 2026
Independent Director of Atara Biotherapeutics Picks Up 272% More Stock - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 16.7 (%) |
| Held by Institutions | 57.6 (%) |
| Shares Short | 322 (K) |
| Shares Short P.Month | 427 (K) |
| EPS | -1.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.93 |
| Profit Margin | -269.5 % |
| Operating Margin | -627.5 % |
| Return on Assets (ttm) | -24.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -96.5 % |
| Gross Profit (p.s.) | 0.46 |
| Sales Per Share | 0.61 |
| EBITDA (p.s.) | -1.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -6.17 |
| PEG Ratio | 0 |
| Price to Book value | -2.05 |
| Price to Sales | 12.99 |
| Price to Cash Flow | -3.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|